Table of Contents
In July 2018, NDMA was detected in valsartan — an angiotensin II receptor blocker (ARB) used by millions. The finding triggered recalls across global markets. By mid-2025, the FDA had overseen more than 40 specific product recalls linked to nitrosamine contaminants, with total API-related recalls exceeding 500 since the crisis began (Shaik et al., 2025, Drugs & Therapy Perspectives). The European Medicines Agency recorded 32 related recalls through the same period.
What most buyers don’t realize: the root cause often traces back to the intermediate synthesis step, not the final API.
Key Takeaway: Nitrosamine formation in pharmaceutical intermediates is a process chemistry problem — not just a final-product quality problem. Intermediate manufacturers who understand the formation pathways can prevent contamination before it enters the downstream supply chain.
The FDA’s September 2024 final guidance (Control of Nitrosamine Impurities in Human Drugs) and the APIC’s May 2025 Nitrosamine Risk Management: Guidance for API Manufacturers identify three primary formation routes that apply directly to intermediate manufacturing:
When a secondary amine (present in many intermediate structures) encounters a nitrosating agent — typically sodium nitrite under acidic conditions — a nitrosamine forms. This is the classic formation mechanism described by the FDA guidance and confirmed in multiple studies (Brambilla et al., 2023, Regulatory Toxicology and Pharmacology).
In intermediate synthesis, this occurs when:
Red Flag for Buyers: If your intermediate’s synthesis route uses both amine-containing compounds and nitrite salts (even in separate steps), the risk of cross-reaction during solvent recovery or equipment cleaning must be assessed.
The FDA guidance explicitly warns: “Recovered materials such as solvents, reagents, and catalysts may pose a risk of nitrosamine impurities due to the presence of residual amines (such as trimethylamine) or nitrosating agents in the recovered material.”
DMF — one of the most widely used solvents in intermediate synthesis — decomposes to dimethylamine (DMA), a direct NDMA precursor. When DMF-containing solvent is recovered and reused in a process that also involves nitrite, the conditions for NDMA formation are established.
This was the exact mechanism in the sartan crisis: the tetrazole ring preparation step used ZnCl₂ and NaN₃ in DMF-based solvent systems, and the recovered solvent carried residual DMA that subsequently formed NDMA upon contact with nitrite sources (Nature, Scientific Reports, 2025).
Multi-product manufacturing facilities present a specific risk. If one product line uses nitrite-based chemistry and another produces an amine-containing intermediate on the same equipment, inadequate cleaning between campaigns can deposit nitrosating residue that reacts with the amine in the next batch.
The WHO TRS 1060 Annex 2 (April 2025, Good Practice Considerations for the Prevention and Control of Nitrosamines) specifically addresses shared facility risk and recommends dedicated equipment or validated cleaning protocols when amine and nitrite processes coexist.
Key Takeaway: For intermediate manufacturers, the formation pathways are process-specific. A risk assessment must trace every amine source and every nitrite source through the entire synthesis route — including recovered materials and equipment histories.
The Carcinogenic Potency Categorization Approach (CPCA), developed by FDA and international regulators through the Nitrosamine International Technical Working Group (NITWG), assigns any nitrosamine to one of five potency categories based solely on its chemical structure — without requiring compound-specific toxicology data (Kruhlak et al., 2024, Regulatory Toxicology and Pharmacology).
CPCA Category | Predicted Carcinogenic Potency | Recommended AI Limit (FDA) | Recommended AI Limit (EMA) | α-Hydrogen Profile |
1 | High | 26.5 ng/day | 18 ng/day | 2,2 / 2,3 / 3,3 |
2 | Medium-High | 26.5 ng/day | 18 ng/day | 0,3 / 1,3 |
3 | Medium | 400 ng/day | 400 ng/day | 0,2 / 1,2 |
4 | Low-Medium | 1,500 ng/day | 1,500 ng/day | Requires deactivating features |
5 | Low | 1,500 ng/day | 1,500 ng/day | 0,0 / 0,1 / 1,1 or tertiary α-carbon |
Why this matters for intermediate buyers: CPCA allows you to determine the acceptable intake limit for any NDSRI unique to your API without waiting for compound-specific data. If your intermediate contains a secondary amine that could form a nitrosamine, you can immediately classify the potential impurity and calculate the specification limit.
CPCA Quick-Check for Intermediate Manufacturers:
1 Identify all secondary amine or tertiary amine sites in your intermediate’s molecular structure.
2 Determine if the process uses nitrite salts, nitrite-containing reagents, or nitrite-contaminated solvents.
3 If both an amine source and a nitrite source exist, apply the CPCA flow chart to the hypothetical nitrosamine formed from the amine + nitrosating agent to determine its potency category and AI limit.
4 Calculate the specification limit: ppm = AI (ng/day) ÷ MDD (mg/day).
Six small-molecule nitrosamines are currently prioritized in FDA and EMA screening protocols. Their AI limits are established with compound-specific data:
Nitrosamine | Abbreviation | AI Limit (ng/day) | Typical Formation Source |
N-nitrosodimethylamine | NDMA | 96 | DMA + nitrite; DMF decomposition |
N-nitrosodiethylamine | NDEA | 26.5 | Diethylamine + nitrite |
N-nitroso-N-methyl-4-aminobutyric acid | NMBA | 96 | Sartan-specific; solvents |
N-nitrosodiisopropylamine | NDIPA | 26.5 | Isopropylamine sources |
N-nitrosoethylisopropylamine | NEIPA | 26.5 | Mixed amine sources |
N-nitrosodibutylamine | NDBA | 26.5 | Dibutylamine + nitrite; also leachable from packaging |
Source: FDA CDER Nitrosamine Impurity Acceptable Intake Limits table (updated June 2026).
NDSRIs (Nitrosamine Drug Substance-Related Impurities) are structurally related to the API itself. They form when the API’s own amine functionality — typically a secondary amine or dimethylamino group — undergoes nitrosation. Every API with an amine center has its own unique potential NDSRI.
For intermediate manufacturers, NDSRI risk is relevant because:
Note on scope: This article addresses nitrosamine risk assessment for pharmaceutical intermediates. ICH M7(R2) provides the overarching framework for mutagenic impurity control. Nitrosamines, as a subset of cohort-of-concern mutagens under ICH M7, carry lower AI limits (18–26.5 ng/day for the most potent categories) than the standard TTC threshold of 1.5 µg/day for non-nitrosamine mutagenic impurities.
Based on the APIC May 2025 guidance framework, a manufacturer-level risk assessment for intermediates follows three stages:
Map every step of the synthesis route to identify:
Evaluate:
Based on the findings from Stages 1 and 2, classify each intermediate into one of three outcomes:
Outcome | Description | Action Required |
No risk identified | No amine source AND no nitrite source exist in the process; no cross-contamination pathway | Document the assessment; no confirmatory testing needed |
Risk identified, but likely controlled | Amine and nitrite sources exist but are separated by process design (e.g., different steps, incompatible pH conditions) | Document the rationale; consider confirmatory testing for verification |
Risk identified, confirmatory testing required | Amine and nitrite sources coexist under nitrosation-favorable conditions, or recovered materials may carry both | Develop and validate a sensitive analytical method (GC-MS/MS or LC-MS/MS); test representative batches |
Key Takeaway: The APIC guidance explicitly states that risk assessment for intermediates should be proportional: if neither an amine nor a nitrite source exists in the process, confirmatory testing is not required. This prevents unnecessary analytical work while ensuring real risks are identified.
Before signing a supply agreement, procurement teams should directly ask:
1 “Does your synthesis route for this intermediate use nitrite salts, sodium azide, or other nitrosating agents?”
If yes, request the specific step(s) and conditions where these reagents are used.
2 “Does the intermediate contain a secondary amine, tertiary amine, or dimethylamino group?”
If yes, the potential NDSRI must be classified via CPCA.
3 “Do you recover and reuse solvents that may carry residual amines or nitrosating species?”
Recovered DMF is a known NDMA risk vector. Request solvent recovery protocol documentation.
4 “Is this intermediate manufactured on shared equipment with nitrite-using processes?”
If yes, request cleaning validation data proving nitrite residue removal.
5 “Have you completed a nitrosamine risk assessment per APIC or FDA guidance, and what was the outcome?”
A supplier who has completed the assessment and can share the outcome classification demonstrates process awareness that a supplier who has not assessed cannot. For a broader evaluation framework, see our supplier audit checklist.
Red Flag 1: No nitrosamine-related specification listed.
If the intermediate contains an amine center and the process uses nitrite, the COA should include a nitrosamine specification — even if the result is “not detected.” Absence of the specification line means the risk was never assessed.
Red Flag 2: “NDMA: Not Detected” without an LOD/LOQ statement.
“Not detected” is meaningless without knowing the detection limit. For NDMA at an AI of 96 ng/day and a typical intermediate daily dose contribution, the required specification may be in the low ppm range. If the method’s LOQ is higher than the specification limit, the test is inadequate.
Red Flag 3: Solvent residue specifications that don’t address DMF decomposition products.
DMF is routinely specified as a residual solvent. But DMA (dimethylamine) — the nitrosation precursor formed from DMF — is rarely listed. A COA that controls DMF but not DMA has a gap in nitrosamine precursor control.
Red Flag 4: The supplier cannot articulate a risk assessment outcome.
If the supplier cannot tell you whether their assessment resulted in “no risk,” “risk likely controlled,” or “confirmatory testing required,” they likely have not conducted one — or the result was unfavorable and undisclosed. For a complete guide on interpreting all COA fields — not just nitrosamine entries — see our article on how to read a COA for pharmaceutical intermediates.
The financial and operational consequences of nitrosamine contamination are documented:
Impact Category | Data | Source |
Total FDA API-related recalls (2018–2025) | 500+ | Shaik et al., 2025 |
Specific product recalls by mid-2025 | 40+ | Shaik et al., 2025 |
EMA recalls through mid-2025 | 32 | EMA/EMRN Report, July 2025 |
ARB market shortage rate (2018–2020 peak) | 15–20% of market | Aclespa, 2026 |
Compliance testing cost (mid-sized manufacturer, annual) | $500K–$2M | Industry estimates, 2025 |
Single reformulation project (metformin line) | 18 months, $2M+ | Industry report, late 2025 |
For intermediate suppliers, the cost extends beyond recalls. A buyer who discovers an undisclosed nitrosamine risk during their own API-level assessment will switch suppliers — and the relationship damage is permanent. Understanding pharmaceutical intermediate pricing factors helps procurement teams quantify the full cost of a failed batch beyond the invoice line.
Date | Regulatory Action | Relevance to Intermediate Manufacturers |
September 2020 | FDA issues first nitrosamine guidance (AI limits for NDMA, NDEA) | Initial screening requirement for all API manufacturers |
March 2021 | Small-molecule nitrosamine risk assessment deadline | API-level assessments begin cascading requirements to intermediate suppliers |
August 2023 | FDA RAIL Guidance: NDSRI AI limits published | Every API with an amine center now has a specific NDSRI limit — intermediate-level risk must be evaluated |
September 2024 | FDA final guidance Rev.2: Control of Nitrosamine Impurities in Human Drugs | Expanded root cause section including recovered solvents and cross-contamination — directly addresses intermediate manufacturing scenarios |
April 2025 | WHO TRS 1060 Annex 2: Prevention and Control of Nitrosamines | First global guidance addressing shared facility risk and periodic reassessment |
May 2025 | APIC: Nitrosamine Risk Management: Guidance for API Manufacturers (updated) | First manufacturer-level guidance with a structured three-outcome assessment framework applicable to intermediates |
June 2025 | FDA softens NDSRI compliance deadline; accepts progress reports | Recognizes the time needed for intermediate-level and API-level reformulation |
August 2025 (original) | NDSRI confirmatory testing and changes submission deadline | Now extended; progress updates accepted via Annual Reports |
Key Takeaway: Regulatory expectations have shifted from “test the final product” to “assess the entire process chain.” Intermediate manufacturers who proactively conduct risk assessments now will avoid the compliance crunch that will accelerate as NDSRI deadlines tighten.
Q: Do all pharmaceutical intermediates require nitrosamine testing?
A: No. If a process chemistry review confirms that no amine source and no nitrite source coexist in the synthesis route, and no cross-contamination pathway exists, confirmatory testing is not required per APIC guidance. Testing is proportional to identified risk.
Q: What is the difference between a small-molecule nitrosamine and an NDSRI?
A: Small-molecule nitrosamines (NDMA, NDEA, NMBA, etc.) are independent chemical compounds not structurally related to the API. NDSRIs are formed by nitrosation of the API’s own amine functionality and share structural similarity with the API. NDSRIs are unique to each drug substance. For intermediates, the distinction matters because the intermediate may contain the same amine center as the final API.
Q: How do I calculate the nitrosamine specification limit in ppm for my intermediate?
A: Use the formula: ppm = AI (ng/day) ÷ MDD (mg/day). The AI depends on the specific nitrosamine or its CPCA category. For NDMA (AI = 96 ng/day) in a drug with a maximum daily dose of 320 mg, the specification limit would be 96 ÷ 320 = 0.3 ppm. For NDEA (AI = 26.5 ng/day) in the same drug, the limit would be 0.083 ppm. Note: for intermediates, the “daily dose contribution” should be calculated based on the intermediate’s mass proportion in the final API dose.
Q: Is recovered DMF always a nitrosamine risk?
A: Recovered DMF is a risk vector, not a guaranteed source of contamination. DMF decomposes to dimethylamine (DMA) under certain conditions. DMA becomes a nitrosation precursor only when it encounters a nitrite source under acidic conditions. The risk depends on whether recovered DMF is used in a process that also involves nitrite, and whether adequate quality checks on recovered solvent are in place.
Q: What analytical methods are used for nitrosamine detection in intermediates?
A: GC-MS/MS and LC-MS/MS are the primary validated methods, capable of detection at parts-per-billion (ppb) levels. GC-MS methods can achieve LOD of 0.005 µg/g for NDMA and 0.001 µg/g for NDEA (Scientific Reports, 2025). LC-MS/MS offers broader applicability for NDSRIs and less volatile nitrosamines. Method selection should match the nitrosamine’s volatility and the intermediate matrix complexity.
Q: Why does FDA recommend 26.5 ng/day for CPCA Category 1 while EMA recommends 18 ng/day?
A: The difference reflects regional policy approaches to the same underlying data. FDA’s 26.5 ng/day is based on compound-specific rodent carcinogenicity data for NDEA. EMA’s 18 ng/day applies the standard cohort-of-concern TTC value as a conservative default. For products marketed in the US, use 26.5 ng/day. For EU markets, use 18 ng/day. Both limits correspond to a theoretical excess cancer risk below 1 in 100,000 over a 70-year lifetime.
This guide explains three formation pathways (amine + nitrite reaction, recovered solvent contamination, and shared-equipment cross-contamination), walks through the CPCA classification framework for assessing risk levels, and provides five questions every procurement team should ask their intermediate supplier — plus four red flags to spot on a COA.
This guide clarifies the three terms (retest date, expiry date, shelf life) with ICH definitions, explains how manufacturers assign retest periods using a risk-based stability framework, and gives you five questions to ask any supplier — plus four red flags to watch for on COA date labels.
A manufacturer’s guide to the six cost layers behind pharmaceutical intermediate pricing—raw materials, synthesis yields, chiral chemistry, purification, waste treatment, and scale—helping buyers evaluate competing quotes and identify hidden risks.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.